Affordable Access

Publisher Website

The neuroprotective effect of mesenchymal stem cells in colistin-induced neurotoxicity.

Authors
  • Öz Gergin, Özlem1
  • Gergin, İsmail Şamil2
  • Pehlivan, Sibel Seckin1
  • Cengiz Mat, Ozge3
  • Turan, Işıl Tuğçe3
  • Bayram, Adnan1
  • Gönen, Zeynep Burçin4
  • Korkmaz, Şeyda4
  • Bıcer, Cihangir1
  • Yildiz, Karamehmet1
  • Yay, Arzu Hanım3, 4
  • 1 Department of Anesthesiology and Reanimation, Medical Faculty, Erciyes University, Kayseri, Turkey. , (Turkey)
  • 2 Department of Neurosurgery, Kayseri City Hospital, Kayseri, Turkey. , (Turkey)
  • 3 Department of Histology and Embryology, Faculty of Medicine, Erciyes University, Kayseri, Turkey. , (Turkey)
  • 4 Genome and Stem Cell Center (GENKOK), Erciyes University, Kayseri, Turkey. , (Turkey)
Type
Published Article
Journal
Toxicology Mechanisms and Methods
Publisher
Informa UK (Taylor & Francis)
Publication Date
Feb 01, 2023
Volume
33
Issue
2
Pages
95–103
Identifiers
DOI: 10.1080/15376516.2022.2090303
PMID: 35702031
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Colistin is an effective antibiotic against multidrug-resistant gram-negative bacterial infections; however, neurotoxic effects are fundamental dose-limiting factors for this treatment. Stem cell therapy is a promising method for treating neuronal diseases. Multipotent mesenchymal stromal cells (MSC) represent a promising source for regenerative medicine. Identification of neuroprotective agents that can be co-administered with colistin has the potential to allow the clinical application of this essential drug. This study was conducted to assess the potential protective effects of MSC, against colistin-induced neurotoxicity, and the possible mechanisms underlying any effect. Forty adult female albino rats were randomly classified into four equal groups; the control group, the MSC-treated group (A single dose of 1 × 106/mL MSCs through the tail vein), the colistin-treated group (36 mg/kg/d colistin was given for 7 d) and the colistin and MSC treated group (36 mg/kg/d colistin was administered for 7 d, and 1 × 106/mL MSCs). Colistin administration significantly increased GFAP, NGF, Beclin-1, IL-6, and TNF-α immunreactivity intensity. MSC administration in colistin-treated rats partially restored each of these markers. Histopathological changes in brain tissues were also alleviated by MSC co-treatment. Our study reveals a critical role of inflammation, autophagy, and apoptosis in colistin-induced neurotoxicity and showed that they were markedly ameliorated by MSC co-administration. Therefore, MSC could represent a promising agent for prevention of colistin-induced neurotoxicity.

Report this publication

Statistics

Seen <100 times